Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 16/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6395050 | 1.00 | FOLH1 (0.55) | FOLH1CYP19A1CYP1A1TYRDOHH | |
| SCHEMBL27349224 | 0.85 | FOLH1 (0.47) | FOLH1CYP19A1CYP1A1 | |
| SCHEMBL24233113 | 0.82 | FOLH1 (0.45) | FOLH1CYP19A1CYP1A1SLC1A3 | |
| SCHEMBL14656409 | 0.82 | FOLH1 (0.45) | FOLH1CYP19A1CYP1A1SLC1A3 | |
| SCHEMBL14656535 | 0.80 | ARG1 (0.52) | FOLH1CYP19A1CYP1A1SLC1A3 | |
| SCHEMBL16964393 | 0.79 | FOLH1 (0.53) | FOLH1CYP19A1CYP1A1 | |
| SCHEMBL25661057 | 0.78 | FOLH1 (0.55) | FOLH1CYP19A1CYP1A1 | |
| SCHEMBL28618096 | 0.77 | FOLH1 (0.48) | FOLH1CYP19A1CYP1A1 | |
| SCHEMBL4153679 | 0.74 | FDPS (0.51) | TYRDOHHKDM4E | |
| SCHEMBL4485559 | 0.74 | CYP19A1 (0.47) | FOLH1CYP19A1CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020230780-A1 | Ras INHIBITORY PEPTIDE | 一丸ファルコス株式会社 | 2020-11-19 | — | — | WO | claimed |
| EP-1191106-B1 | Process for the fermentative preparation of non-proteinogenic L-amino acids | CONSORTIUM ELEKTROCHEM IND (DE) | 2004-04-28 | — | — | EP | claimed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| CN-114585637-B | MASP-inhibitory compounds and uses thereof | 拜耳公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| EP-3004138-B1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LTD (IE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4309673-A2 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | Bausch Health Ireland Limited (IE) | 2024-01-24 | — | — | EP | disclosed |
| US-20240002440-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | JPMORGAN CHASE BANK, N.A. | 2024-01-04 | — | — | US | disclosed |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20060258593-A1 | Methods and compositions for the treatment of gastrointestinal disorders | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2006-11-16 | — | — | US | disclosed |
| WO-2006086653-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20060094658-A1 | Method and compositions for the treatment of gastrointestinal disorders | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2006-05-04 | — | — | US | disclosed |
| US-7015331-B2 | Non-proteinogenic L-amino acids | Consortium für elektrochemische Industrie GmbH (DE) | 2006-03-21 | — | — | US | disclosed |
| US-20050222426-A1 | Non-proteinogenic L-amino acids | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH | 2005-10-06 | — | — | US | disclosed |
| US-6939967-B2 | Non-proteinogenic L-amino acids | Consortium für elektrochemische Industrie GmbH (DE) | 2005-09-06 | — | — | US | disclosed |
| US-20040197879-A1 | Process for producing non-proteinogenic L-amino acids by fermentation | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH | 2004-10-07 | — | — | US | disclosed |
| US-6756216-B2 | BATCH PROCESSING USING NUCLEOPHILIC COMPOUND | Consortium für elektrochemische Industrie GmbH (DE) | 2004-06-29 | — | — | US | disclosed |
| US-20020039767-A1 | Process for producing non-proteinogenic L-amino acids by fermentation | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222426-A1 | Non-proteinogenic L-amino acids | BCAT2, BCAT1, CBS | FOLH1 512/4885CYP19A1 2151/4885CYP1A1 1920/4885 |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | FOLH1 1560/4885CYP19A1 4805/4885CYP1A1 4205/4885 |
| US-20060258593-A1 | Methods and compositions for the treatment of gastrointestinal disorders | GRPR, GIPR, GCGR | FOLH1 3375/4885CYP19A1 4781/4885CYP1A1 4533/4885 |
| US-20020039767-A1 | Process for producing non-proteinogenic L-amino acids by fermentation | CBS, BCAT2, BCAT1 | FOLH1 885/4885CYP19A1 2983/4885CYP1A1 2033/4885 |
| US-20060094658-A1 | Method and compositions for the treatment of gastrointestinal disorders | GRPR, GCGR, GIPR | FOLH1 2985/4885CYP19A1 4801/4885CYP1A1 4673/4885 |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | SLC34A3, SLC34A2, SLC34A1 | FOLH1 548/4885CYP19A1 4751/4885CYP1A1 4489/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | FOLH1 1560/4885CYP19A1 4805/4885CYP1A1 4205/4885 |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | FOLH1 1184/4885CYP19A1 630/4885CYP1A1 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.